Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease.

Gohda T, Kamei N, Koshida T, Kubota M, Tanaka K, Yamashita Y, Adachi E, Ichikawa S, Murakoshi M, Ueda S, Suzuki Y.

J Diabetes Investig. 2019 Sep 4. doi: 10.1111/jdi.13139. [Epub ahead of print]

2.

Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease.

Takahashi K, Ueda S, Kobayashi T, Nishiyama A, Fujisawa Y, Sugaya T, Shiota S, Takahashi K, Gohda T, Horikoshi S, Suzuki Y.

Sci Rep. 2018 Dec 18;8(1):17926. doi: 10.1038/s41598-018-36159-9.

3.

Effect of Zinc Acetate Dihydrate (NobelzinR) Treatment on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with Hypozincemia.

Sato D, Gohda T, Kihara M, Kanaguchi Y, Kobayashi T, Mano S, Sasaki Y, Nohara N, Murakoshi M, Nakata J, Suzuki H, Ueda S, Horikoshi S, Suzuki Y.

Acta Med Okayama. 2018 Oct;72(5):535-538. doi: 10.18926/AMO/56254.

4.

Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes.

Kamei N, Yamashita M, Nishizaki Y, Yanagisawa N, Nojiri S, Tanaka K, Yamashita Y, Shibata T, Murakoshi M, Suzuki Y, Gohda T.

Sci Rep. 2018 Oct 17;8(1):15302. doi: 10.1038/s41598-018-33590-w.

5.

Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease.

Gohda T, Nishizaki Y, Murakoshi M, Nojiri S, Yanagisawa N, Shibata T, Yamashita M, Tanaka K, Yamashita Y, Suzuki Y, Kamei N.

Diabetes Res Clin Pract. 2018 Jul;141:62-68. doi: 10.1016/j.diabres.2018.04.026. Epub 2018 May 3.

PMID:
29729375
6.

Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS.

Shimizu M, Furuichi K, Toyama T, Funamoto T, Kitajima S, Hara A, Ogawa D, Koya D, Ikeda K, Koshino Y, Kurokawa Y, Abe H, Mori K, Nakayama M, Konishi Y, Samejima KI, Matsui M, Yamauchi H, Gohda T, Fukami K, Nagata D, Yamazaki H, Yuzawa Y, Suzuki Y, Fujimoto S, Maruyama S, Kato S, Naito T, Yoshimura K, Yokoyama H, Wada T; Research Group of Diabetic Nephropathy, the Ministry of Health, Labour, and Welfare of Japan and Japan Agency for Medical Research and Development.

Clin Exp Nephrol. 2018 Apr;22(2):377-387. doi: 10.1007/s10157-017-1467-9. Epub 2017 Sep 9.

PMID:
28889347
7.

Effect of tonsillectomy with steroid pulse therapy on circulating tumor necrosis factor receptors 1 and 2 in IgA nephropathy.

Murakoshi M, Gohda T, Sonoda Y, Suzuki H, Tomino Y, Horikoshi S, Suzuki Y.

Clin Exp Nephrol. 2017 Dec;21(6):1068-1074. doi: 10.1007/s10157-017-1408-7. Epub 2017 Apr 7.

PMID:
28389814
8.

High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia.

Nishimon S, Ohnuma T, Takebayashi Y, Katsuta N, Takeda M, Nakamura T, Sannohe T, Higashiyama R, Kimoto A, Shibata N, Gohda T, Suzuki Y, Yamagishi SI, Tomino Y, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:145-154. doi: 10.1016/j.pnpbp.2017.03.006. Epub 2017 Mar 22.

PMID:
28341443
9.

High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia.

Sannohe T, Ohnuma T, Takeuchi M, Tani E, Miki Y, Takeda M, Katsuta N, Takebayashi Y, Nakamura T, Nishimon S, Kimoto A, Higashiyama R, Shibata N, Gohda T, Suzuki Y, Yamagishi SI, Tomino Y, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:42-48. doi: 10.1016/j.pnpbp.2017.02.019. Epub 2017 Mar 7.

PMID:
28282638
10.

Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis.

Gohda T, Maruyama S, Kamei N, Yamaguchi S, Shibata T, Murakoshi M, Horikoshi S, Tomino Y, Ohsawa I, Gotoh H, Nojiri S, Suzuki Y.

Sci Rep. 2017 Mar 3;7:43520. doi: 10.1038/srep43520.

11.

Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy.

Maruyama S, Gohda T, Suzuki Y, Suzuki H, Sonoda Y, Ichikawa S, Li Z, Murakoshi M, Horikoshi S, Tomino Y.

Kidney Res Clin Pract. 2016 Dec;35(4):233-236. Epub 2016 Sep 16.

12.

[Treatment of diabetic nephropathy, particularly focusing on drug therapy].

Gohda T.

Nihon Rinsho. 2016 Apr;74 Suppl 2:202-6. Japanese. No abstract available.

PMID:
27266088
13.

Podocyte-specific deletion of Rac1 leads to aggravation of renal injury in STZ-induced diabetic mice.

Ishizaka M, Gohda T, Takagi M, Omote K, Sonoda Y, Oliva Trejo JA, Asao R, Hidaka T, Asanuma K, Horikoshi S, Tomino Y.

Biochem Biophys Res Commun. 2015 Nov 20;467(3):549-55. doi: 10.1016/j.bbrc.2015.09.158. Epub 2015 Oct 21.

PMID:
26435502
14.

The Prevalence and Management of Diabetic Nephropathy in Asia.

Tomino Y, Gohda T.

Kidney Dis (Basel). 2015 May;1(1):52-60. doi: 10.1159/000381757. Epub 2015 Apr 30. Review.

15.

Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy.

Sonoda Y, Gohda T, Suzuki Y, Omote K, Ishizaka M, Matsuoka J, Tomino Y.

PLoS One. 2015 Apr 10;10(4):e0122212. doi: 10.1371/journal.pone.0122212. eCollection 2015.

16.

Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia.

Takeda M, Ohnuma T, Takeuchi M, Katsuta N, Maeshima H, Takebayashi Y, Higa M, Nakamura T, Nishimon S, Sannohe T, Hotta Y, Hanzawa R, Higashiyama R, Shibata N, Gohda T, Suzuki Y, Yamagishi S, Tomino Y, Arai H.

Neurosci Lett. 2015 Apr 23;593:51-5. doi: 10.1016/j.neulet.2015.03.002. Epub 2015 Mar 10.

PMID:
25766756
17.

Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria.

Skupien J, Warram JH, Niewczas MA, Gohda T, Malecki M, Mychaleckyj JC, Galecki AT, Krolewski AS.

Diabetes Care. 2014 Sep;37(9):2601-8. doi: 10.2337/dc13-1983. Epub 2014 Jun 4.

18.

Combat diabetic nephropathy: from pathogenesis to treatment.

Gohda T, Mima A, Moon JY, Kanasaki K.

J Diabetes Res. 2014;2014:207140. doi: 10.1155/2014/207140. Epub 2014 Mar 11. No abstract available.

19.

Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice.

Omote K, Gohda T, Murakoshi M, Sasaki Y, Kazuno S, Fujimura T, Ishizaka M, Sonoda Y, Tomino Y.

Am J Physiol Renal Physiol. 2014 Jun 1;306(11):F1335-47. doi: 10.1152/ajprenal.00509.2013. Epub 2014 Mar 19.

20.

Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Krolewski AS, Gohda T, Niewczas MA.

Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12. Review.

21.

Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH.

Diabetes Care. 2014;37(1):226-34. doi: 10.2337/dc13-0985. Epub 2013 Aug 12.

22.

Association of the cardioankle vascular index and ankle-brachial index with carotid artery intima media thickness in hemodialysis patients.

Gohda T, Gotoh H, Gotoh Y, Yamaguchi S, Tomino Y.

Int J Nephrol. 2013;2013:401525. doi: 10.1155/2013/401525. Epub 2013 Jun 24.

23.

Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.

Furukawa M, Gohda T, Hagiwara S, Tanimoto M, Horikoshi S, Funabiki K, Tomino Y.

Int J Nephrol. 2013;2013:519130. doi: 10.1155/2013/519130. Epub 2013 Jun 2.

24.

Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy.

Furukawa M, Gohda T, Tanimoto M, Tomino Y.

ScientificWorldJournal. 2013 Apr 24;2013:928197. doi: 10.1155/2013/928197. Print 2013. Review.

25.

Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.

Gohda T, Tomino Y.

Curr Diab Rep. 2013 Aug;13(4):560-6. doi: 10.1007/s11892-013-0385-9. Review.

PMID:
23657763
26.

[Factors associated with cardiovascular death and events in patients with end stage renal disease].

Yamaguchi S, Gohda T, Gotoh H, Omote K, Furukawa M, Ishikawa Y, Tomino Y.

Nihon Jinzo Gakkai Shi. 2013;55(2):159-66. Japanese.

PMID:
23631303
27.

Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.

Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA.

PLoS One. 2013;8(3):e58007. doi: 10.1371/journal.pone.0058007. Epub 2013 Mar 20.

28.

Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice.

Ishikawa Y, Gohda T, Tanimoto M, Omote K, Furukawa M, Yamaguchi S, Murakoshi M, Hagiwara S, Horikoshi S, Funabiki K, Tomino Y.

Exp Diabetes Res. 2012;2012:702948. doi: 10.1155/2012/702948. Epub 2012 Jul 26. Review.

29.

The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS.

Kidney Int. 2012 Sep;82(5):589-97. doi: 10.1038/ki.2012.189. Epub 2012 May 23.

30.

Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes.

Gohda T, Walker WH, Wolkow P, Lee JE, Warram JH, Krolewski AS, Niewczas MA.

Am J Physiol Renal Physiol. 2012 Jul 1;303(1):F157-62. doi: 10.1152/ajprenal.00443.2011. Epub 2012 Apr 18.

31.

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.

Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):516-24. doi: 10.1681/ASN.2011060628. Epub 2012 Jan 19.

32.

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):507-15. doi: 10.1681/ASN.2011060627. Epub 2012 Jan 19.

33.

Role of mindin in diabetic nephropathy.

Murakoshi M, Gohda T, Tanimoto M, Funabiki K, Horikoshi S, Tomino Y.

Exp Diabetes Res. 2011;2011:486305. doi: 10.1155/2011/486305. Epub 2011 Dec 26. Review.

34.

Lowered LDL-C Levels Reduce Later Local Vascular Events after Surgical or Endovascular Treatment of Peripheral Artery Disease.

Ishii K, Takahashi J, Kanaoka T, Wakamatsu Y, Gohda T, Sasaki S, Matsui Y.

Ann Vasc Dis. 2012;5(2):180-9. doi: 10.3400/avd.oa.12.00003.

35.

Lowered postoperative ldl-c/hdl-C ratio reduces later cardiovascular events after abdominal aortic aneurysm surgery.

Kanaoka T, Takahashi J, Wakamatsu Y, Ishii K, Gohda T, Sasaki S, Matsui Y.

Ann Vasc Dis. 2012;5(1):36-44. doi: 10.3400/avd.oa.11.00068. Epub 2011 Dec 9.

36.

Effects of dialysis on the pharmacokinetics of salazosulfapyridine.

Inami Y, Yamaji K, Sato M, Gohda T, Io H, Nawata M, Hamada C, Takasaki Y, Tomino Y.

Rheumatol Int. 2013 Feb;33(2):535-9. doi: 10.1007/s00296-011-2179-1. Epub 2011 Nov 12.

PMID:
22080212
37.

Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice.

Aoki T, Kaneko S, Tanimoto M, Gohda T, Hagiwara S, Murakoshi M, Ishikawa Y, Furukawa M, Funabiki K, Horikoshi S, Tomino Y.

J Nephrol. 2012 Jan-Feb;25(1):127-36. doi: 10.5301/JN.2011.8433.

PMID:
21725918
38.

AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction.

Tomino Y, Hagiwara S, Gohda T.

Kidney Int. 2011 Jul;80(2):133-5. doi: 10.1038/ki.2011.86.

39.

Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice.

Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ, Tomino Y.

Am J Physiol Renal Physiol. 2011 Jun;300(6):F1271-82. doi: 10.1152/ajprenal.00065.2010. Epub 2011 Mar 2.

40.

Preoperative HDL-C Predicts Later Cardiovascular Events after Abdominal Aortic Aneurysm Surgery.

Takahashi J, Wakamatsu Y, Ishii K, Kanaoka T, Gohda T, Sasaki S, Matsui Y.

Ann Vasc Dis. 2011;4(2):115-20. doi: 10.3400/avd.oa.11.00024. Epub 2011 Jun 2.

41.

Mindin: a novel marker for podocyte injury in diabetic nephropathy.

Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Takagi M, Horikoshi S, Tomino Y.

Nephrol Dial Transplant. 2011 Jul;26(7):2153-60. doi: 10.1093/ndt/gfq708. Epub 2010 Nov 22.

PMID:
21098016
42.

Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice.

Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y.

Nephron Exp Nephrol. 2011;117(4):e124-32. doi: 10.1159/000320284. Epub 2010 Oct 13.

PMID:
20948237
43.

Predictive factors associated with left ventricular hypertrophy at baseline and in the follow-up period in non-diabetic hemodialysis patients.

Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T, Shimizu Y, Tomino Y.

Semin Dial. 2011 May-Jun;24(3):349-54. doi: 10.1111/j.1525-139X.2010.00759.x. Epub 2010 Aug 13.

PMID:
20723158
44.

Metabolic impact on serum levels of complement component 3 in Japanese patients.

Ohsawa I, Inoshita H, Ishii M, Kusaba G, Sato N, Mano S, Onda K, Gohda T, Horikoshi S, Ohi H, Tomino Y.

J Clin Lab Anal. 2010;24(2):113-8. doi: 10.1002/jcla.20372.

PMID:
20333766
45.

Type B insulin resistance syndrome with systemic lupus erythematosus.

Sato N, Ohsawa I, Takagi M, Gohda T, Horikoshi S, Shirato I, Yamaguchi Y, Tomino Y.

Clin Nephrol. 2010 Feb;73(2):157-62.

PMID:
20129024
46.

Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice.

Yamazaki T, Tanimoto M, Gohda T, Ohara I, Hagiwara S, Murakoshi M, Matsumoto M, Kaneko S, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y.

Nephron Exp Nephrol. 2009;113(2):e66-76. doi: 10.1159/000228714. Epub 2009 Jul 16.

PMID:
19609084
47.

Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients.

Gotoh H, Gohda T, Tanimoto M, Gotoh Y, Horikoshi S, Tomino Y.

Nephrol Dial Transplant. 2009 Nov;24(11):3474-80. doi: 10.1093/ndt/gfp290. Epub 2009 Jun 17.

PMID:
19535435
48.

Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice.

Hagiwara S, Gohda T, Tanimoto M, Ito T, Murakoshi M, Ohara I, Yamazaki T, Matsumoto M, Horikoshi S, Funabiki K, Tomino Y.

Metabolism. 2009 Jul;58(7):934-45. doi: 10.1016/j.metabol.2009.02.033.

PMID:
19427656
49.

Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.

Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I, Toyoda H, Ishikawa Y, Horikoshi S, Tomino Y.

Diabetes Res Clin Pract. 2009 Feb;83(2):183-9. doi: 10.1016/j.diabres.2008.11.008. Epub 2009 Jan 13.

PMID:
19144436
50.

Maximum aortic diameter as a simple predictor of acute type B aortic dissection.

Takahashi J, Wakamatsu Y, Okude J, Kanaoka T, Sanefuji Y, Gohda T, Sasaki S, Matsui Y.

Ann Thorac Cardiovasc Surg. 2008 Oct;14(5):303-10.

PMID:
18989246

Supplemental Content

Support Center